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The availability of a noninvasive method to detect and quantify apoptosis in tumours will enable tumour response to several cancer
therapies to be assessed. We have synthesised two radiotracers, annexin V and the N-succinimidyl-3-iodobenzoic acid (SIB)
derivative of annexin V, labelled with radio-iodine (
124I and
125I) and provided proof of the concept by assessing specific binding and
biodistribution of these probes to apoptotic cells and tumours. We have also assessed the tumour uptake of [
124I]annexin V in a
mouse model of apoptosis. RIF-1 cells induced to undergo apoptosis in vitro showed a drug concentration-dependent increased
binding of [
125I]annexin V and [
125I]SIB–annexin V. In the same model system, there was an increase in terminal deoxynucleotidyl
transferase-mediated nick end labelling (TUNEL)-positive cells and a decrease in clonogenic survival. Radiotracer binding was
completely inhibited by preincubation with unlabelled annexin V. In RIF-1 tumour-bearing mice, rapid distribution of [
125I]SIB–
annexin V-derived radioactivity to kidneys was observed and the radiotracer accumulated in urine. The binding of [
125I]SIB–annexin
V to RIF-1 tumours increased by 2.3-fold at 48h after a single intraperitoneal injection of 5-fluorouracil (165mgkg
 1 body weight),
compared to a 4.4-fold increase in TUNEL-positive cells measured by immunostaining. Positron emission tomography images with
both radiotracers demonstrated intense localisation in the kidneys and bladder. Unlike [
124I]SIB–annexin V, [
124I]annexin V also
showed localisation in the thyroid region presumably due to deiodination of the radiolabel. [
124I]SIB–annexin V is an attractive
candidate for in vivo imaging of apoptosis by PET.
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There is an increasing need for the development of assays to
determine the pharmacodynamic effects of new cancer therapeu-
tics (Workman, 2002). Since assays that require tumour samples
have a number of limitations, development of less invasive imaging
technologies is extremely important (Workman, 2002). Evasion of
programmed cell death (apoptosis) is a phenotypic hallmark that
is shared by most human tumours (Hanahan and Weinberg, 2000).
Pathways leading to apoptosis are now considered valid targets for
cancer chemotherapy (Sellers and Fisher, 1999). Apoptosis is also
the outcome of treatment with radiation and several chemotherapy
agents and, therefore, a noninvasive method of quantifying
changes in apoptosis will be an attractive pharmacodynamic end
point for anticancer therapies. Such pharmacodynamic end points
are critical in the development of new molecular therapeutics
(Workman, 2002). Beyond oncology, the methodology may
potentially be applicable in neurodegenerative diseases, transplant
rejection and autoimmune disease.
Externalisation of phosphatidylserine (PS) is a general feature of
apoptosis. During apoptosis, deactivation of the enzymes translo-
case and floppase, which maintain PS in the inner leaflet of the
plasma membrane, together with activation of the enzyme
scramblase, result in the redistribution of PS on the outer surface
of the membrane (Martin et al, 1995; Zwaal and Schroit, 1997).
These processes occur prior to membrane blebbing and DNA
degradation. Annexin-V, a 35kDa calcium-dependent protein,
binds with high affinity (K¼10
 9 m) specifically to PS residues
that are displayed on the outer surface of apoptotic cells (Martin
et al, 1995). This means that in the intact animal or patient,
apoptosis can be detected by imaging the binding of radiolabelled
annexin V to PS. Using single-photon emission computed
tomography (SPECT), a number of research groups have imaged
PS expression with [
99mTc]-radiolabelled annexin V during cardiac
allograft rejection, fas-mediated fulminant hepatic apoptosis and
in a murine model of cyclophosphamide-induced apoptosis
(Blankenberg et al, 1998, 1999, 2001; Narula et al, 2001; Mochizuki
et al, 2003).
The levels of apoptosis induced in the above models are high in
comparison to what is usually achievable in animal and human
solid tumours following chemotherapy or biological therapy
(Aboagye et al, 1998; David et al, 1999; Griffon-Etienne et al,
1999; Herbst et al, 2002). We have developed positron-labelled
annexin V that can ultimately be used for imaging apoptosis in Received 25 April 2003; revised 10 July 2003; accepted 14 July 2003
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stumours by positron emission tomography (PET). In theory, PET
should provide higher sensitivity and resolution for imaging
apoptosis than SPECT, although the latter is more widely available.
The objective of the present study was to determine the feasibility
of using iodinated-annexin V to detect apoptosis in tumours and
to validate the methodology by comparison to classical measures
of apoptosis in vitro and in vivo. Annexin V can be radiolabelled
with
125I directly, to give [
125I]annexin V, or indirectly, to give the
N-succinimidyl iodobenzoic acid derivative ([
125I]SIB–annexin V).
We investigated both nonisotopically labelled peptides, comparing
specific binding to PS and deiodination of the radiolabel in vivo.
The limitations of using radiolabelled annexin V to detect
apoptosis, including the fact that it binds to both apoptotic and
necrotic cells, are discussed.
MATERIALS AND METHODS
Radiolabelling of annexin V
Polyhistidine-tagged annexin V was prepared according to
standard molecular biology procedures. Briefly, the coding region
of annexin V was amplified from a Jurkat cDNA library using
gene-specific primers and was inserted into pProEXHTb by
BamHI/EcoRI digestion. Polyhistidine-tagged annexin V was
induced in Escherichia coli, DH5a strain, and subsequently
purified from bacterial lysates by incubation with nickel-nitrilo-
triacetic acid (Ni-NTA) resin. The purified annexin-V protein was
eluted from the Ni-NTA resin in the presence of 100mm imidazole.
Imidazole was subsequently removed by extensive washing in
annexin V binding buffer (1.8mm CaCl2,1 0m m HEPES-NaOH pH
7.4, 150mm NaCl, 5mm KCl and 1mm MgCl2). The polyhistidine-
tagged annexin V was shown to be active by a modified
competition assay using a fluorescene isothiocyanate (FITC)-
annexin V kit (BD PharMingen, San Diego, CA, USA). The annexin
V was directly radiolabelled with either iodine-125 (for in vitro and
biodistribution studies) or
124I (for PET imaging studies) as
previously described (Glaser et al, 2003). [
125I]SIB and [
124I]SIB
were synthesised according to published methods (Garg et al, 1989;
Koziorowski et al, 1998; Glaser et al, 2003) and purified by normal-
phase high-performance liquid chromatography (HPLC). Labelling
of annexin V with [
125I]SIB/[
124I]SIB was performed according to
the method of Glaser et al (2003). All iodinated-proteins
([
125I]annexin V, [
125I]SIB–annexin V, [
124I]annexin V and
[
124I]SIB–annexin V) were purified on a PD10 column. The
radiochemical purity of effluents was determined by instant thin-
layer chromatography and sodium dodecyl sulphate–polyacryla-
mide gel electrophoresis. Protein concentrations for the determi-
nation of pseudo-specific radioactivity were measured by the BCA
assay (Peribo Science, Chester, UK).
Binding of radiolabelled annexin V to apoptotic cells
in vitro
The biological activity of radiolabelled annexin V was evaluated in
exponentially growing RIF-1 fibrosarcoma (adherent) cells treated
with 5-fluorouracil (5-FU) at 3 and 30mm for 24h (5% CO2
incubator at 371C). Control (phosphate-buffered saline; PBS) and
5-FU-treated cells were washed twice with PBS and 5ml of annexin
V binding buffer added. To determine specific binding, some cells
were preincubated for 15min with 100  unlabelled annexin V
before the addition of radiolabelled annexin. Cells were incubated
with either [
125I]annexin V (20–25mCi) or [
125I]SIB–annexin V
(3–4mCi) on a Gyro rocker at room temperature for 1h. After
incubation, cells were scraped and centrifuged (5000r.p.m. for
5min at 41C) to obtain the pellet. The pellet was washed with PBS
(5ml), centrifuged and the resulting pellet was dissolved in 0.6ml
of 1% Triton X. Aliquots of this solution were used for assessment
of protein content as described above. Aliquots were also counted
on a g-counter (Packard, Pangbourne, UK) to determine the
percentage of radioactivity in labelled cells, that is, %bound
radioactivity¼[100 bound radioactivity/(total radioactivi-
ty protein content)]. All experiments were performed in
triplicate and repeated three times.
Determination of apoptosis by flow cytometry
The extent of apoptosis in the model systems described was
evaluated by flow cytometry. A hallmark of apoptosis is extensive
degradation of chromosomal DNA into oligomers of B180 base
pairs producing large numbers of free 30-hydroxy deoxynucleotide
ends. The terminal deoxynucleotidyl transferase-mediated nick
end labelling (TUNEL) assay measures these 30-hydroxy deox-
ynucleotide ends (Gavrieli et al, 1992). To perform this assay,
RIF-1 cells were treated as above and fixed in PBS containing
1% (wv
 1) paraformaldehyde (methanol-free). Cells were incu-
bated in 70% ethanol on ice for 30min and stained using the
ApoDirect TUNEL assay kit (PharMingen). The proportion of
apoptotic cells was determined by flow cytometry (gated to
exclude aneuploidy). Fluorescent activated cell sorting (FACS)
analysis of FITC-stained cells was performed using the WinMDI
software (FACS Care Facility, Scripps Research Institute, San
Diego, CA, USA).
Clonogenic survival
In addition to biochemical measures of apoptosis, the extent of
radiolabelled annexin V labelling of RIF-1 cells was also compared
to clonogenic survival, a ‘gold standard’ of cell death. Control
(PBS) and 5-FU-treated (3 or 30mm for 24h) cells were harvested
by trypsinisation and diluted in serum-enriched media (1000, 3500
cellsml
 1 for control; 1000, 3500, 10000 cellsml
 1 for 3mm; and
7000, 10000 cellsml
 1 for 30mm). The cells (1ml) were plated in
Petri dishes and incubated for 7–10 days. The plates were stained
with crystal violet (0.2% in 70% ethanol) and the resulting colonies
were counted. The surviving fraction was determined by compar-
ing the number of colonies in control cells to that of treated cells.
Four plates were used for each dose level and the experiment was
repeated three times.
Biodistribution of radiolabelled annexin V
The biodistribution of [
125I]SIB–annexin V was evaluated in C3H/
Hej mice (Harlan, Oxfordshire, UK) bearing RIF-1 tumours. All
animal work was performed by licensed investigators in accor-
dance with the United Kingdom’s ‘Guidance on the Operation of
Animals (Scientific Procedures) Act 1986’ (HMSO, London, UK,
1990) and in full compliance with government regulations and
UKCCCR guidelines on animal welfare (Workman et al, 1998). To
obtain tumours, 5 10
5 RIF-1 cells were injected into the rear
dorsum subcutis of the mice. Tumours were selected for
biodistribution studies when they had reached 5–8mm in
diameter (100–300mg). Tumour-bearing mice were injected
intravenously via the lateral tail vein with 0.1ml of [
125I]SIB–
annexin V (2–3mCi). At selected times after injection (2, 10, 30, 60
and 120min), mice were killed by exsanguination via cardiac
puncture under general anaesthesia (isofluorane inhalation).
Aliquots of heparinised blood were rapidly centrifuged (2000g
for 5min) to obtain plasma. The radioactivity contained in the
tumour, liver, kidney, spleen, lungs, stomach, heart, small
intestines, large intestines, brain, muscle, bone blood, plasma,
faeces and urine was determined in a g-counter (Packard) and
expressed as a percentage of injected dose per gram of tissue
(%IDg
 1). A minimum of three mice were used for each time
point.
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sUptake of radiolabelled annexin V by apoptotic tumours
in vivo
To establish whether drug-induced apoptosis in tumours
results in increased radiolabelled annexin uptake in vivo, the
uptake of [
125I]annexin V and [
125I]SIB–annexin V was deter-
mined in mice treated with PBS (control) or 5-FU at a single
intraperitoneal dose of 165mgkg
 1 (48h prior to the radiotracer
experiments). RIF-1-bearing mice were injected intravenously
via the lateral vein with 0.1ml of [
125I]annexin V or [
125I]SIB–
annexin V (3–4mCi). To determine the specificity of radio-
labelled annexin V binding, a modified competition assay was
performed in which a separate cohort of mice were injected
intravenously with unlabelled annexin V at 1h before the
[
125I]annexin V injection. The concentration of unlabelled
annexin V in this case was 100-fold greater than that in the
injectate of [
125I]annexin V. At 60min postinjection of radiola-
belled annexin V, mice were killed by exsanguination via cardiac
puncture under general anaesthesia. The radioactivity contained in
the tumour was determined in a g-counter and expressed as
tumor:blood ratio. A minimum of three mice were used for each
time point.
Determination of apoptosis in vivo by
immunohistochemistry
Similar to the in vitro studies, the extent of apoptosis in the in vivo
model system described above was evaluated using a modification
of the TUNEL immunohistochemistry method previously de-
scribed by Aboagye et al (1998). Briefly, control (PBS) and 5-FU-
treated (165mgkg
 1 intraperitoneally (i.p.); 48h after treatment)
RIF-1 tumours were excised and fixed in formal saline. The
tumours were then embedded in paraffin for sectioning. Paraffin-
embedded histological sections (5mm) were deparaffinised,
treated with proteinase K and stained using the ApoDirect
TUNEL assay kit (PharMingen). The sections were mounted
in a medium containing propidium iodide (PI) (Sigma, Poole,
Dorset, UK) and viewed by fluorescence microscopy (Olympus
BX51, Olympus Optical, Tokyo, Japan) with a dual filter for FITC
and PI. The number of apoptotic (green fluorescence) cells in each
field of view ( 40 magnification; 0.55mm
3) was counted. Two
slices from three tumours per treatment group were evaluated; 10
fields of view were randomly selected (in light microscopy mode)
for analysis.
Imaging of radiolabelled annexin V in mice by PET
Initial whole-body PET imaging with
124I radiolabelled annexin
was performed to evaluate the imaging potential of the tracer in
mice. RIF-1 tumour-bearing mice were treated with a single
injection of 5-FU (165mgkg
 1 i.p.) to induce apoptosis and
scanned 48h after 5-FU treatment. For PET scanning, the tail
veins of the mice were cannulated after induction of anaesthesia
with isofluorane/N2O/O2. For each scan, a tumour-bearing
animal was placed prone within a thermostatically controlled
jig and positioned in the bore of the scanner. [
124I]Annexin V
or [
124I]SIB–annexin V (10–40mCi) prepared in PBS was injected
via the tail cannula. Emission scans were acquired on a quad-
HIDAC small animal scanner (Oxford Positron Systems,
Oxfordshire, UK) in list-mode format. Animals were scanned
for 1h from the time of injection. The acquired list-mode
data were sorted into 0.5mm sinogram bins for image
reconstruction (3D image pixel size – 0.5 0.5 0.5mm). A single
static frame from 30 to 60min postinjection was obtained
and visualised using the image analysis software, Analyze
(version 4.0; Biomedical Imaging Resource, Mayo Clinic,
Rochester, MN, USA).
Statistical analysis
Statistical analyses were performed using GraphPad Prism,
Version 2.0C (GraphPad Software Inc., San Diego, CA, USA).
Errors were expressed as a standard error of the mean (s.e.m.). The
significance of comparisons between two data sets was determined
using Student’s t-test for two independent populations. The
significance of comparison between more than two data sets was
determined using a one-way analysis of variance. Pp0.05 was
considered significant.
RESULTS
Radiochemical profile of iodinated annexin V
The radiochemical yield, pseudospecific radioactivity and radio-
chemical purity of [
124I]annexin V were 22.3%, 14.5GBqmmol
 1,
and 97.7%, respectively. The radiochemical yield, pseudospecific
radioactivity and radiochemical purity of [
124I]SIB–annexin V
were 25% (from [
124I]SIB), 1.6GBqmmol
 1 and 96.7%, respec-
tively. The radiotracers were stable for up to 4 days without
significant deiodination (Glaser et al, 2003).
Radiolabelled annexin V binds to apoptotic cells in vitro
Figure 1 shows the binding of radiolabelled annexin V to
RIF-1 cells. [
125I]annexin V and [
125I]SIB–annexin V both showed
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Figure 1 In vitro binding of radioiodinated annexin V to control (PBS)
and 5-FU treated (3 and 30mm) RIF-1 cells. (A)[
125I]SIB–annexin V and
(B)[
125I]annexin V. Data were expressed as %bound radioactivity (mg
protein)
 1. Data are mean7s.e.m. (n¼9).
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shigher binding in treated cells compared to control cells
(P¼0.0001). The extent of binding was dependent on the
concentration of 5-FU added. These results indicate that both
methods of radiolabelling annexin V yield biologically active
radiotracers. The proportion of radiotracer that was bound to
apoptotic cells (%bound radioactivity (mg protein)
 1) was,
however, higher in the case of [
125I]SIB–annexin V. A large
decrease in radiotracer binding following pretreatment with
unlabelled annexin V demonstrated the specificity of radiolabelled
annexin V binding. It should be noted that radiotracer binding in
this instance was lower than that of controls, indicating significant
pretreatment levels of annexin-binding sites in control cells.
Similar results were seen in HL60 cells treated with camptothecin
at 5mm for 6h (data not shown).
The radiotracer binding data were compared to results
obtained with TUNEL staining and clonogenic survival.
Figure 2A shows a typical flow cytometry output for control and
5-FU-treated cells. An increased proportion of apoptotic
(FITC positive; PI negative) and necrotic (FITC positive; PI
positive) cells was observed after 5-FU treatment. The percentage
of TUNEL-positive apoptotic cells increased with drug treat-
ment in a drug-concentration-dependent manner (P¼0.0001;
Figure 2B). In keeping with the drug-induced increase in
apoptosis, there was a decrease in clonogenic survival of 15.5
and 41.4% (P¼0.0001) at 5-FU concentrations of 3 and 30mm,
respectively (Figure 2C).
Biodistribution of radiolabelled annexin V
The biodistribution of [
125I]SIB–annexin V in RIF-1 bearing C3H/
Hej mice is shown in Figure 3. [
125I]SIB–annexin V distributed
well into all tissues. The radioactivity profiles in all tissues showed
a rapid uptake such that the highest radioactivity was seen at the
first time point (2min). The washout of radioactivity was slower.
Overall, the highest tissue radioactivities were seen in kidneys and
urine. At early time points, radioactivity in the blood, heart, lungs,
spleen and liver was higher than that in untreated tumours,
%
 
A
p
o
p
t
o
s
i
s
 
(
r
e
l
a
t
i
v
e
 
t
o
 
c
o
n
t
r
o
l
)
0
5
10
15
Control
Control 3 µM 30 µM 
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
0.0
0.5
1.0
5-FU concentration
Control 3 µM 30 µM 
5-FU concentration
15.5% cell kill
41.4% cell kill
Treated (30 µM 5FU)
Necrotic
Apoptotic
FITC
P
I
FITC
104
104 103 102 101 100 104 103 102 101 100
103
102
101
100
P
I
104
103
102
101
A
B
C
Figure 2 5-Fluorouracil-induced cell death in RIF-1 cells in vitro.( A) Flow
cytometry of TUNEL-stained control (PBS treated) and 5-FU treated
(30mm) cells. Data were analysed by setting quadrants on the FACS data
such that 1% of control cells were in the lower right quadrant (FITC
positive – PI negative; apoptotic cells); the same quadrant was then placed
on the FACS data from corresponding treated cells. (B) Proportion of
apoptotic cells relative to control cells. Data are mean7s.e.m. (n¼4). (C)
Clonogenic survival of control and 5-FU-treated cells expressed as a
fraction of controls. Data are mean7s.e.m. (n¼12).
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Figure 3 Biodistribution of [
125I]SIB–annexin V in untreated RIF-1
tumour bearing C3H/Hej mice at 2, 10, 30, 60 and 120min. Data from (A)
tumour, liver, kidney, spleen, lungs, stomach, heart and small intestines, and
(B) large intestines, brain, muscle, bone, blood, plasma, faeces and urine.
The two panels show data from the same group of mice; note that the Y-
axis is different for the two panels. Data are mean7s.e.m. (n¼3–5 per
time point).
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salthough the clearance from these tissues was more rapid. This
observation was important in the selection of 1h as the optimal
time for evaluating apoptosis in tumours.
Radiolabelled annexin V localises in apoptotic tumours
in vivo
We hypothesised that the proof of mechanism of action of
radiolabelled annexin V in vivo will involve a higher uptake in
apoptotic tumours compared to control tumours. The 48h time
point had the highest uptake after treatment (data not shown) and,
thus, used for subsequent experimentation. In keeping with the
above hypothesis, the uptake of indirectly radiolabelled tracer,
[
125I]SIB–annexin V, was found to be 2.3-fold higher in 5-FU-
treated tumours (48h postinjection) compared to control tumours
(P¼0.04; Table 1). In contrast, there was a nonsignificant change
(P¼0.91) in the uptake of the directly radiolabelled tracer,
[
125I]annexin V, in 5-FU-treated tumours compared to control
tumours (Table 1). The binding of [
125I]annexin V to annexin V-
binding sites was, however, found to be specific as indicated by the
ability to block uptake by pretreatment of mice with excess
unlabelled annexin V (P¼0.04).
The radiotracer-binding characteristics were in keeping with
TUNEL immunostaining of histological sections. Figure 4A shows
representative TUNEL-stained section of control and 5-FU-treated
RIF-1 tumours. TUNEL-stained cells are seen in both sections. The
number of TUNEL-positive cells increased by 4.4-fold after 5-FU
treatment (P¼0.0001; Figure 4B). A substantial reduction in
tumour volume was seen at 48h post 5-FU injection (43%;
P¼0.05; Figure 4C).
Imaging of radiolabelled annexin V in mice by PET
Positron emission tomography offers the potential of imaging
radiolabelled-annexin V binding with high sensitivity and resolu-
tion (temporal and spatial). Thus, we imaged 5-FU-treated RIF-1
tumour-bearing mice (48h post-treatment) with either [
124I]an-
nexin V or [
124I]SIB–annexin V in a dedicated small animal PET
scanner. Representative 30–60min maximum intensity projection
images are shown in Figure 5. Due to the low radiochemical yield,
the amount of radiotracer injected in both cases was low. This did
not permit the full potential of dynamic imaging to be achieved.
The static image data were, however, in general agreement with the
biodistribution data showing high uptake in the kidney and
bladder regions. The main difference between the two radiotracers
was a high uptake of radioactivity in the thyroid in the case of
[
124I]annexin V. In this study, we did not detect the tumour by PET
imaging.
DISCUSSION
The experiments described in this paper underpin the potential
utility of iodinated annexin V as a radiotracer for imaging
apoptosis by PET. Direct and indirect methods of radiolabelling
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Figure 4 5-Fluorouracil-induced cell death in RIF-1 cells in vivo.( A)
Representative 5mm immunohistochemical (TUNEL) sections of control
and 5-FU treated (165mgkg
 1 i.p.; 48h postinjection) tumours;  400
magnification. (B) The average number of apoptotic cells (TUNEL positive)
per field of view (0.55mm
2) for control and 5-FU-treated groups. Two
slices from three tumours were analysed for each group; for each section,
10 fields of view were randomly selected for the analysis. (C) Mean tumour
size of pretreated (control) and 5-FU-treated (165mgkg
 1 i.p.; 48h
postinjection) mice. There was a 43% reduction of tumour volume. Data
are mean7s.e.m. (n¼6, pretreated; n¼3, 5-FU-treated).
Table 1 Effect of 5-FU on the tumour uptake of [
125I]SIB–annexin V and
[
125I]annexin V in vivo in control and 5-FU-treated (165mgkg
 1 i.p.; 48h
post-treatment) mice
[
125I]SIB–annexin V [
125I]annexin V
Control 0.3670.05
a 0.9470.17
5-FU treated 0.8470.16 0.9970.05
Challenge ND 0.5570.03
In all mice, the radiotracer was injected and biodistribution studies were performed at
60min. In one group of mice (challenge experiment), 5-FU-treated mice were
pretreated with 100 times unlabelled annexin V at 60min prior to radiotracer
injection. 5-FU¼5-fluorouracil; SIB¼N-succinimidyl-3-iodobenzoic acid.
aData are
mean tumour-to-blood ratios7s.e.m. (n¼3–10).
[124I]Annexin V [124I]SIB−Annexin V
Caudal
AB
Figure 5 Maximum intensity projection PET images of 5-FU treated
(165mgkg
 1 i.p.; 48h postinjection) RIF-1 tumour-bearing C3H/Hej mice
injected with (A)4 0mCi of [
124I]annexin V or (B)1 0mCi [
124I]SIB–annexin
V. All time frames from 30 to 60min (for all coronal planes) were summed
to give an indication of retention. With both radiotracers, there was
localisation of radioactivity in the kidneys and bladder; the flank tumours
were not visible. In the case of [
124I]annexin V, there was localisation of
radioactivity in the thyroid region. Orientation¼tail at the bottom of the
image; head at the top.
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sannexin V with radioiodine were employed to synthesise
[
125I]annexin V and [
125I]SIB–annexin V, respectively. Direct
iodination yielded higher pseudospecific activity product than
indirect labelling with SIB. In vitro analysis demonstrated that the
two radiotracers were biologically active, although the absolute
proportion of the bound tracer was higher in the case of [
125I]SIB–
annexin V. Although there was qualitative agreement between
radiotracer uptake, TUNEL flow cytometry staining and clono-
genic survival data in these in vitro studies, there were significant
quantitative differences. The increase in radiotracer binding
between 3 and 30mm 5-FU was at least 10-fold lower than the
corresponding changes in flow cytometry and clonogenic survival
data. These differences may be explained by the different phases of
the apoptotic process detected by annexin V vs TUNEL (Martin
et al, 1995), as well as the ability to gate out nonspecific effects in
the flow cytometry studies. The survival data would suggest that
small changes in radiotracer binding could lead to larger changes
in clonogenic survival.
Positron emission tomography images of mice showed an
absence of radioactivity in the thyroid region with [
125I]SIB–
annexin V, suggesting that the indirect iodination with SIB led to a
product that was more stable to deiodination in vivo. This finding
is in agreement with the work of Russell et al, who demonstrated
that indirect labelling (Bolton-Hunter) of annexin V gave a
product that was more stable to deiodination than [
125I]annexin
V (Russell et al, 2002). In theory, SIB should be more stable to
deiodination than Bolton-Hunter given the presence of a para-
hydroxyl group (iodine in meta-position) in the latter. Deiodina-
tion leads to lower specific labelling of PS, which may explain why
a significant increase in labelling was seen with the indirectly
radiolabelled annexin V, but not the directly radiolabelled product.
Thus, [
124I]SIB–annexin V appears to be a superior radiotracer for
PET imaging of apoptosis in vivo, although its radiochemical yield
needs to be improved further to enable quantitative kinetic
measurements to be performed. Alternatively, the phenyl-contain-
ing precursors can be reacted with
18F
  to form prosthetic groups
for the synthesis of 18F-radiolabelled annexin (Vaidyanathan and
Zalutsky, 1992). Fluorine-18-radiolabelled annexin will have a
higher proportion of photons (B75% higher) and lower positron
energy, thus providing the potential to perform kinetic measure-
ments and improve image quality. The development of other
positron-emitting isotopes (
11C and
68Ga) conjugated to annexin V
has been reported at recent imaging meetings. With regard to
clinical imaging, these other radiotracers may have advantages
including lower organ absorbed dose due to their shorter half-lives
and higher resolution due to their lower positron energy. Due to its
long half-life, however,
124I-radiolabelled annexin V can be made
widely available to many PET centres.
The in vivo models that have been used in the past to study
apoptosis by radiolabelled annexin V have largely been noncancer
model systems or models that give artificially high levels of
apoptosis (Blankenberg et al, 1998, 1999, 2001; Hofstra et al, 2000;
Ogura et al, 2000; Narula et al, 2001; Kown et al, 2002; Russell et al,
2002). Here, we tested the feasibility of detecting the relatively
small changes (2–6-fold over pretreatment levels; 3–5%) in
apoptosis that are usually achievable in animal and human solid
tumours following chemotherapy or biological therapy (Aboagye
et al, 1998; David et al, 1999; Griffon-Etienne et al, 1999; Herbst
et al, 2002). We have provided proof of concept for the use of
radiolabelled annexin V to detect changes in apoptosis in vivo in
tumours. Radiotracer uptake was found to be associated with an
increase in TUNEL-stained cells, a decrease in clonogenic survival
and tumour shrinkage. [
125I]SIB–annexin V was more discrimi-
natory than [
125I]annexin V for this purpose. The binding of
[
125I]annexin V to PS could be blocked in vitro and in vivo by
excess of unlabelled annexin V. In either situation, the levels of
radiotracer binding in the blocking studies were less than that of
control cells. This could be due to the presence of apoptotic cells in
the untreated control cells. In this study, we did not detect the
tumour by PET imaging. The inability to detect the (flank) tumour
by PET may be due to its proximity to the kidney and bladder,
which had very high uptake values. Even though in vivo [
124I]SIB–
annexin V failed to detect apoptosis in our model system, other
experiments employing annexin V indirectly radiolabelled with
99mTc have demonstrated the feasibility to localise cell death in
regions distant from the liver and kidneys (Belhocine, 2002).
This technology has a number of limitations that need to be
considered in the translation of these preclinical studies into
clinical trials: (i) untreated tumours showed low radiotracer uptake
(%IDg
 1) compared to that of the kidney, urine, liver, lung and
spleen, and induction of apoptosis did not produce a high image
contrast for tumours. Coregistration with magnetic resonance or
X-ray computed tomography images may be required to aid
tumour definition. (ii) The very high localisation of radioactivity
specifically in the kidney and urine may lead to low signal-to-
background ratio and ‘spill over’ in the clinical PET imaging of
kidney and bladder tumours, which could affect quantification.
The high localisation of radiolabelled annexin in the kidney has
been reported by other workers (Blankenberg et al, 1998, 1999).
Although the reason for this nonspecific uptake is not fully
understood, it is likely related to the unique phospholipids
composition of the renal cortex, which has higher amounts of PS
compared to the papillary regions. Another explanation is the
nonspecific uptake of low-molecular-weight proteins such as
annexin V by the proximal renal tubule cells (Blankenberg et al,
1999). (iii) Necrotic cells will be expected to bind to radiolabelled
annexin V. In this regard, initial studies have shown that heat
treatment of HL60 cells leads to substantial radiotracer binding
(DR Collingridge and EO Aboagye, unpublished data). Thus,
unless there is prior evidence of low necrotic death following drug
treatment, which is the case for 5-FU treatment of RIF-1 tumours
in vivo (Aboagye et al, 1998), changes in radiolabelled annexin V
binding should be interpreted as changes in cell death rather than
changes in apoptosis. In the clinical development of [
124I]SIB–
annexin V for cancer therapy monitoring, additional measures of
viability, for example, the exchanging H2
15O space in tissues by PET
(Wilson et al, 1992) or T2 relaxation maps by MRI (Heywang et al,
1987), may be required to differentiate between apoptosis and
necrosis. (iv) PET imaging with radiolabelled annexin V provides a
‘snapshot’ of apoptosis. For translation into clinical application,
the challenge will be the determination of when to scan
(Blankenberg, 2002). In this study, we selected 48h post-treatment
as the time point to image cell death, based on previous studies
that indicated a peak in the apoptotic index at this time point
(Aboagye et al, 1998). More extensive studies are required to show
whether this time coincides with peak annexin V binding.
Belhocine et al (2002) demonstrated an increase in labelling of
human tumours with [
99mTc]annexin V and SPECT at 24–48h
after the first course of chemotherapy. This agrees with reports by
Ellis et al (1997), for instance, of increased apoptosis in human
breast tumours measured in the biopsy specimen, 24h after a
course of chemotherapy. In general, the pharmacokinetics profile
(peak concentration, time to achieve peak concentration, half-life,
steady-state concentration and exposure) and mechanism of action
(DNA interacting drugs vs signal transduction inhibitors, for
instance) of administered drugs are important considerations in
selection of the optimal time for the post-treatment scan. In
addition, serial studies may be required to establish the optimal
imaging protocol that will give maximal tumour/normal tissue
contrast and signal intensity.
In conclusion, we have provided proof of principle for the use of
iodine-labelled annexin V in detecting chemotherapy-induced
apoptosis in vitro and in tumour-bearing mice. The method
provides a ‘snapshot’ of apoptotic cells (and possibly necrotic cells
as well). The small changes in radio-annexin binding are
associated with larger changes in clonogenic survival or tumour
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sshrinkage. [
124I]SIB–annexin V in particular, warrant further
preclinical and clinical development as a probe for imaging
apoptosis induced by chemotherapeutic agents.
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